---

President, Lubrizol Life Sciences – CDMO Division

Lee holds more than two dozen issued patents or provisional patent applications and, through his more than 30 years’ experience in pharmaceutical research and development, he maintains strong academic ties as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas. Alongside his work as a reviewer for the International Journal of Pharmaceutics and the Journal of Pharmaceutical Sciences, Lee serves on the Editorial Boards of the MOJ Bioequivalence & Bioavailability, Journal of Analytical and Pharmaceutical Research, and the scientific pages of Nanotechnology.

We asked…

What would you say to people who think the small molecule drug development field lacks the same growth opportunities as biopharma and cell & gene?

There is plenty of innovation in the small molecule space, including computational methods that may lead to better target molecules with exquisite selectivity, and drug delivery systems (both drug device combination products and complex formulation approaches) that can help deliver these to their intended target and improve compliance, safety, and the overall patient experience. Small molecule drug development isn’t going anywhere soon.

Who would you invite to your dream dinner party?  

I would love to have an outdoor music festival for a few hundred friends and family. The food would be divine and include everything from salads to steaks, ribs to sushi, Dungeness crab and lobster to Kalbi. There would be long jams with many of my music heroes – both still with us and no longer here. The lineup would be epic – Jimi Hendrix, Jeff Beck, Santana, Eric Clapton, Steely Dan, the Beatles, Yes, Led Zeppelin, the Rolling Stones, Lee Ritenour, Larry Carlton, Al Di Meola … and some of these bands would actually invite me to sit in on some of the jams! Joyous music would fill the air for days!